Preclinical ADA AnalysisADA Screening and ConfirmationADA Titer DeterminationLongitudinal ADA Profiling
Creative Peptides provides anti-drug antibody sample testing for preclinical programs evaluating peptides, proteins, antibodies, conjugates, and other biologic research candidates. We support tiered ADA analysis from initial screening through specificity confirmation, titer determination, and longitudinal interpretation of serial samples. Testing can be performed with an established project method or coordinated with our immunogenicity testing and analytical method development and validation capabilities. Each study is planned around the drug format, research species, sample matrix, dosing schedule, expected drug concentrations, available controls, and intended data use.
ADA sample analysis can become difficult when the biological matrix, residual study drug, soluble target, baseline reactivity, or sample collection schedule affects assay response. A single reactive signal does not establish specificity, response magnitude, or persistence. The testing strategy must distinguish assay background from drug-specific binding and preserve subject-level relationships across study time points.
Our anti-drug antibody sample testing services address practical study challenges such as:
Our service scope can be configured for individual study batches, complete preclinical sample sets, or transferred testing programs. Before analysis, we review the assay procedure, sample inventory, plate layout requirements, cut points, controls, dilution scheme, drug-tolerance information, and reporting expectations. This helps ensure that sample results are generated and interpreted according to a consistent project-specific testing cascade.
We perform ADA sample analysis for preclinical studies using the relevant serum or plasma matrix and an agreed assay procedure. Testing plans are aligned with the dosing design, collection schedule, research species, available sample volume, and expected study drug exposure.
Deliverables can include sample-level results, run summaries, control performance, repeat-test history, and study-level result tables.
Tiered screening and confirmation help separate potentially reactive samples from samples that demonstrate drug-specific binding under the established assay conditions.
Confirmation is especially important when the sample matrix, drug architecture, conjugated components, or assay reagents can produce non-specific reactivity.
Confirmed ADA-positive samples can be evaluated across serial dilutions to estimate the relative magnitude of the binding-antibody response.
Titer results support comparison of response magnitude among subjects and across time points, but should be interpreted as assay-dependent relative measurements rather than absolute antibody concentrations.
Serial sample analysis provides more information than an isolated result because ADA responses can appear, increase, decrease, or disappear during and after a repeat-dose study.
When exposure or pharmacokinetic data are supplied, ADA results can also be aligned with concentration-time profiles to support study interpretation without assuming a causal relationship.
Client-developed or externally developed ADA methods can be transferred for sample analysis when the required procedure, reagents, controls, cut points, and supporting method information are available.
Transfer planning helps reduce inconsistencies caused by reagent handling, equipment settings, incubation timing, calculation methods, or differences in matrix preparation.
ADA data packages are prepared to make sample status, testing history, quality-control performance, and longitudinal relationships clear to research and bioanalytical teams.
Reporting formats can be aligned with the sponsor's study tables and data-review workflow to simplify internal assessment and cross-functional communication.
Longitudinal anti-drug antibody analysis evaluates more than whether an individual sample is positive or negative. Baseline status, confirmation results, titer changes, sampling intervals, residual drug concentrations, and recovery-period samples should be reviewed together. The table below summarizes common preclinical ADA response patterns and the follow-up actions that may support clearer study interpretation.
| ADA Response Pattern | Typical Sample Profile | Interpretation Focus | Recommended Follow-Up | Reporting Consideration |
|---|---|---|---|---|
| No Detected Response | Baseline and all evaluable post-dose samples are below the screening threshold | Determine whether sampling times and demonstrated drug tolerance were sufficient to detect a potential response | Review residual drug exposure, sample integrity, assay controls, and collection timing | Report as ADA negative under the tested assay conditions rather than as evidence that antibodies were completely absent |
| Pre-Existing Stable Reactivity | Baseline sample is confirmed positive, with no project-defined increase in post-dose response or titer | Separate pre-existing binding from a treatment-associated increase | Compare baseline and post-dose titers using the same method and dilution scheme | Classify as pre-existing reactivity without treatment-associated boosting when supported by the predefined rules |
| Boosted Pre-Existing Response | Baseline sample is confirmed positive and one or more post-dose samples show a project-defined increase in response magnitude | Determine whether the post-dose change exceeds expected assay and titer variability | Confirm sample identity, repeat critical time points when justified, and review the complete titer profile | Describe the response as treatment-boosted only when the predefined increase criterion is met |
| Transient Treatment-Induced Response | Baseline is negative, one or more post-dose samples are confirmed positive, and later evaluable samples return to negative | Assess onset, peak titer, duration, and whether later negative results could be affected by residual drug | Review recovery samples, drug concentrations, assay drug tolerance, and adjacent collection time points | Use a project-defined temporal rule before classifying the response as transient |
| Persistent Treatment-Induced Response | Baseline is negative and confirmed ADA positivity is observed at multiple post-dose time points, including a later or recovery sample | Evaluate response duration, titer trajectory, and consistency across consecutive collections | Complete titer testing and align the ADA profile with available exposure or pharmacokinetic data | Define persistence according to the study schedule and predefined classification criteria |
| Isolated Late Response | Only a terminal or recovery-period sample is confirmed positive | Determine whether the result represents delayed onset, an earlier undetected response, or isolated assay reactivity | Review screening and confirmation data, determine titer, and examine the spacing of earlier sample collections | Avoid assigning onset or persistence when intermediate samples are unavailable |
| Fluctuating Response | Confirmed positive and negative results alternate across serial post-dose samples | Consider responses near the assay threshold, changing drug concentrations, sample quality, and analytical variability | Review raw signals, confirmatory inhibition, titers, drug tolerance, and repeat-test history | Present the complete subject-level timeline rather than reducing the pattern to a single positive or negative classification |
| Interference-Limited Result | The sample contains residual drug above demonstrated tolerance, has insufficient volume, fails acceptance criteria, or cannot complete confirmation | Determine whether a valid ADA status can be assigned from the available evidence | Consider permitted pretreatment, alternative dilution, repeat analysis, or testing of another time point | Report the sample as qualified, inconclusive, or not evaluable rather than automatically classifying it as ADA negative |
Sample testing quality depends on both the analytical method and the study design. The following factors should be reviewed before samples are assigned to screening, confirmation, and titer runs.
| Study Factor | Potential Testing Problem | Planning Approach | Reporting Consideration |
|---|---|---|---|
| Residual Study Drug | Drug–ADA complexes can reduce detectable free ADA and produce false-negative or underestimated responses | Review expected exposure, collection timing, drug tolerance, dilution, and permitted sample pretreatment | Flag samples collected when drug concentrations may exceed demonstrated assay tolerance |
| Species Matrix | Endogenous immunoglobulins, complement, soluble proteins, or non-specific binding may elevate background | Use study-relevant pooled matrix, matrix controls, and established assay cut points | Describe matrix-specific background or control shifts observed during testing |
| Pre-Existing Reactivity | Baseline binding can be mistaken for a newly induced response | Include pre-dose samples and define rules for evaluating post-dose increases | Separate baseline-positive, post-dose emerging, and boosted response categories |
| Drug Architecture | Linkers, PEG, carriers, tags, fusion partners, or conjugated components may create additional antibody specificities | Determine whether the whole drug, individual components, or both are needed for confirmation or follow-on testing | Avoid assigning component specificity unless the required experiments were performed |
| Sampling Schedule | Sparse or poorly timed collections can miss the onset, peak, or decline of an ADA response | Align baseline, post-dose, repeat-dose, recovery, and terminal collections with the study objective | State when response persistence cannot be resolved from the available time points |
| Sample Integrity | Repeated freeze–thaw cycles, prolonged storage, hemolysis, lipemia, or contamination may alter assay behavior | Define sample acceptance, storage, shipment, aliquoting, and freeze–thaw limits before testing | Record deviations and identify results that require cautious interpretation |
| Limited Sample Volume | Insufficient volume may prevent confirmation, titer testing, repeats, or follow-on characterization | Prioritize the testing cascade, use efficient plate layouts, and reserve aliquots when possible | Distinguish negative results from samples that could not complete the full testing cascade |
Tiered Testing Logic
Screening, confirmation, titer, and longitudinal review are connected through predefined decision rules rather than treated as unrelated assay runs.
Matrix-Aware Planning
The testing plan considers research species, serum or plasma type, matrix background, soluble factors, and available baseline controls.
Interference Risk Review
Residual drug, soluble target, conjugated components, and sample condition are reviewed before results are interpreted.
Subject-Level Traceability
Samples, repeats, dilutions, confirmation results, and titers remain linked across time points for clearer longitudinal evaluation.
Flexible Method Transfer
Established sponsor methods can be transferred with structured review of procedures, reagents, controls, calculations, and operational variables.
Decision-Focused Reporting
Data packages emphasize sample status, response magnitude, time-course behavior, quality controls, repeats, and known interpretation limitations.
Our workflow connects study design information, assay requirements, controlled sample testing, and longitudinal interpretation so that each reported ADA result can be traced to the applicable procedure and decision rule.
1
Study and Assay Review
2
Sample Inventory Planning
3
Screen and Confirm
4
Titer and Timeline
5
QC and Reporting
Anti-drug antibody sample testing supports preclinical teams when immune-response data are needed to interpret exposure, compare candidates, assess repeat-dose studies, or investigate unexpected subject-level findings.
Creative Peptides supports preclinical anti-drug antibody sample analysis from screening and specificity confirmation through titer determination and longitudinal data review. To scope a project, provide the drug format, research species, sample matrix, study design, collection schedule, sample count, available volume, assay status, controls, expected drug exposure, and reporting requirements. Contact us to discuss your testing cascade, method-transfer needs, and sample-analysis plan.
Serum or plasma is commonly tested. The species, anticoagulant, collection procedure, storage conditions, and assay matrix should be defined before analysis.
Screening identifies potentially reactive samples. Confirmation evaluates whether that reactivity is specifically inhibited by the study drug or meets another predefined specificity criterion.
A confirmed positive sample is tested across serial dilutions. The titer is based on the highest dilution that remains above the method-specific endpoint threshold.
Not necessarily. ADA titer is a relative, assay-dependent measurement influenced by antibody affinity, assay format, matrix effects, and the defined dilution procedure.
Residual drug can bind ADA and mask it from the assay. Sampling time, drug tolerance, sample dilution, and permitted pretreatment procedures should be reviewed before interpretation.
